SCHEMBL979407

SCHEMBL979407

O=C(C=Cc1ccccc1)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 12/20 0.78
MAOB P27338 6/20 0.78
MAPT P10636 5/20 0.78
TNFRSF1A P19438 2/20 0.78
PLIN1 O60240 1/20 0.78
LMNA P02545 1/20 0.78
BCHE P06276 1/20 0.78
ACHE P22303 1/20 0.78
RECQL P46063 1/20 0.78
PLIN5 Q00G26 1/20 0.78
ABHD5 Q8WTS1 1/20 0.78
KMT2A Q03164 4/20 0.73
HSPD1 P10809 3/20 0.73
HSPE1 P61604 3/20 0.73
CYP3A4 P08684 3/20 0.73
MEN1 O00255 2/20 0.73
MAOA P21397 2/20 0.73
ALDH2 P05091 1/20 0.73
CYP19A1 P11511 1/20 0.73
F3 P13726 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14045042 1.00 CYP1B1 (0.78) CYP1B1MAOBMAPTTNFRSF1APLIN1
SCHEMBL976912 0.96 CYP1B1 (0.71) CYP1B1MAOBMAPTTNFRSF1APLIN1
SCHEMBL12306205 0.96 CYP1B1 (0.71) CYP1B1MAOBMAPTTNFRSF1APLIN1
Chalcone SCHEMBL28027252 0.94 CYP1B1 (0.88) CYP1B1MAOBMAPTTNFRSF1APLIN1
SCHEMBL29672076 0.93 CYP1B1 (0.72) CYP1B1MAOBMAPTTNFRSF1APLIN1
SCHEMBL657749 0.92 MAPT (0.78) CYP1B1MAOBMAPTTNFRSF1APLIN1
SCHEMBL657748 0.92 MAPT (0.78) CYP1B1MAOBMAPTTNFRSF1APLIN1
SCHEMBL25205675 0.91 CYP1B1 (0.65) CYP1B1MAOBMAPTTNFRSF1APLIN1
SCHEMBL25189612 0.91 CYP1B1 (0.65) CYP1B1MAOBMAPTTNFRSF1APLIN1
SCHEMBL25285070 0.91 CYP1B1 (0.90) CYP1B1MAOBMAPTTNFRSF1APLIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114551791-B Composite positive plate containing monocrystal high-nickel positive electrode material and all-solid-state battery 万向一二三股份公司 2024-02-02 CN claimed
CN-114551791-A Composite positive plate containing single crystal high nickel positive electrode material and all-solid-state battery 万向一二三股份公司 2022-05-27 CN claimed
CN-114551791-B Composite positive plate containing monocrystal high-nickel positive electrode material and all-solid-state battery 万向一二三股份公司 2024-02-02 CN disclosed
CN-114551791-A Composite positive plate containing single crystal high nickel positive electrode material and all-solid-state battery 万向一二三股份公司 2022-05-27 CN disclosed
US-7872029-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN J PHILLIP 2011-01-18 US disclosed
US-20090018167-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states Robinson, Thomas Philip (US) 2009-01-15 US disclosed
US-7432303-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states Bowen, J. Phillip (US) 2008-10-07 US disclosed
US-20050148599-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2005-07-07 US disclosed
US-6906105-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN J PHILLIP (US) 2005-06-14 US disclosed
US-20030027830-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2003-02-06 US disclosed
US-6462075-B1 USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2002-10-08 US disclosed
EP-1242352-A2 CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2002-09-25 EP disclosed
US-20020040029-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN, J. PHILLIP 2002-04-04 US disclosed
WO-2001046110-A2 CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040029-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, FLT4, VEGFA CYP1B1 780/4885MAOB 2579/4885MAPT 1111/4885
US-20090018167-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, FLT4, VEGFA CYP1B1 747/4885MAOB 2526/4885MAPT 1274/4885
US-20030027830-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, VEGFA, FLT4 CYP1B1 604/4885MAOB 1509/4885MAPT 341/4885
US-20050148599-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, VEGFA, FLT4 CYP1B1 604/4885MAOB 1509/4885MAPT 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.